Mirum Pharmaceuticals Inc Aktie News

ESCONDIDO, Calif.--(BUSINESS WIRE)--Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 (formerly ENT-3379), Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), in December, reported the initiation of the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragil...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference.

The AI bubble won't burst, but the S&P 500 won't deliver a fourth consecutive year of double-digit returns in 2026. Small-cap, mid-cap, and renewable energy stocks could perform well in the new year.

Fox is Newsmax's primary rival and should remain much bigger than Newsmax by the end of the decade. Mirum Pharmaceuticals is a small drugmaker that's poised to deliver tremendous growth.

Boston-based Eventide Asset Management sold 114,922 shares of Mirum Pharmaceuticals during the third quarter. Despite the sale, the overall value of the position increased by about $50.70 million from the previous period thanks to a staggering stock price surge.

This biotech stock reached an all-time high and is in a buy zone. The company makes drugs for rare diseases.

Mirum Pharmaceuticals, Inc. retains a Buy rating, supported by positive interim analyses for VOLIXIBAT in both PBC [VANTAGE] and PSC [VISTAS] phase 2b trials. Key catalysts include VISTAS topline data in Q2 2026, VANTAGE topline data in H1 2027, and phase 3 EXPAND enrollment completion in 2026. Company strengthened its balance sheet with $200M gross proceeds from Bluejay Therapeutics acquisitio...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX.